[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550859":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":28,"locations":37,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Crohn's disease patients with no-to-mild inflammation",null,"On MR enterography, the Magnetic Resonance Index of Activity (MaRIA) and Magnetic Resonance Enterography Global Score (MEGS) were used to characterize intestinal inflammation by assessing intramural and extramural lesions in both the small and large intestines. In ileocolonoscopy, the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD) was used to quantify mucosal or luminal lesions from the terminal ileum to the colorectum. Both modalities were used to classify patients with no-to-mild or moderate-to-severe inflammation. We defined patients as having moderate-to-severe inflammation when at least two of the following criteria were met: (1) MaRIA≥11; (2) MEGS≥ 10 for the small bowel or MEGS≥12 for the colon; or (3) SES-CD≥11. Otherwise, patients were categorized as having no-to-mild inflammation.",[13],"Diagnostic Test: Logistic regression (LR) prediction models",{"label":15,"type":10,"description":11,"interventionNames":16},"Crohn's disease patients with moderate-to-severe inflammation",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"DIAGNOSTIC_TEST","Logistic regression (LR) prediction models","Logistic regression model was used to establish a model to distinguish different levels of intestinal inflammation.",[15,9],[24],{"name":25,"affiliation":26,"role":27},"Xuehua Li","Sun Yat-sen University First Affiliated Hospital Department of Radiology","PRINCIPAL_INVESTIGATOR",[29,33],{"name":25,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","13580364103","lxueh@mail.sysu.edu.cn",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Ruonan Zhang","15124748450","zhangrn25@mail2.sysu.edu.cn",[38],{"facility":39,"status":40,"city":41,"state":10,"zip":10,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"XploreMET v3.0 system","RECRUITING","Shanghai","China","CN",{"type":45,"coordinates":46},"Point",[47,48],121.45806,31.22222,{"lat":48,"lon":47},[51],{"name":25,"role":30,"phone":10,"phoneExt":10,"email":10},{"type":27,"investigatorFullName":25,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"associate chief physician","100550859","neurophenotype-predicts-cd-disease-progression-100550859",false,"NCT06452550","Neurophenotype Predicts CD Disease Progression","Multimodal MRI-based Neurophenotype Reflecting Brain-gut Interactions to Predict Intestinal Disease Progression in Patients With Crohn's Disease","Inclusion Criteria:\n\n* (a) CD patients aged 18-45 years; (b) the completion of multimodal brain MRI and administration of psychological questionnaires; (c) MR enterography (MRE), ileocolonoscopy, and blood or faecal samples, collection within one week of brain MRI; (d) a follow-up of at least six months for patients without disease progression; and (e) right-handedness.\n\nExclusion Criteria:\n\n* (a) recent use of antibiotics, probiotics, or prebiotics within three months prior to inclusion; (b) history of neurosurgery, cerebrovascular disease, or brain trauma; (c) use of central nervous system drugs or antidepressants within three months prior to inclusion; (d) identification of brain lesions on MR scan; (e) claustrophobia; or (f) presence of metal implants.",true,"ALL","18 Years","45 Years",{"count":66,"type":67},500,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of Crohn's Disease patients and assess its ability for predicting disease progression, using multiomics data to interpret the model.\n\nParticipants will be followed-up of at least six months for patients without disease progression to assess the relationship between neurophenotype and intestinal outcomes.",[71,72],"Radiomics","Multi-omics",[74,75,76,77],"Abdominal MRI","Magnetic Resonance Imaging","Crohn's disease","Brain\u002Fgut interaction","2024-06-05",{"date":80,"type":81},"2024-06-11","ACTUAL",{"date":83,"type":81},"2021-05-01",{"date":85,"type":67},"2025-06-01",{"name":5,"class":6},1]